P-gp+ve Cells Are Resistant to Different Caspase-Dependent Chemotherapeutic Drugs
| . | 125I . | 51Cr . | ZVAD-fmk . | ZFA-fmk . | |||
|---|---|---|---|---|---|---|---|
| 125I . | 51Cr . | 125I . | 51Cr . | . | |||
| CCRF | 55.1 ± 0.1 | 28.7 ± 2.0 | 12.1 ± 1.7 | 5.1 ± 0.0 | 48.5 ± 0.1 | 31.2 ± 4.0 | |
| 2H6 | 53.1 ± 1.1 | 37.8 ± 4.0 | 8.2 ± 1.6 | 7.8 ± 1.9 | 57.7 ± 5.4 | 46.4 ± 0.7 | Vinblastine |
| A7+ | 12.6 ± 1.5 | 7.2 ± 1.7 | 9.2 ± 0.4 | 2.7 ± 0.7 | 15.2 ± 2.5 | 7.6 ± 0.5 | |
| IC10 | 12.5 ± 5.9 | 6.8 ± 0.5 | 10.8 ± 2.3 | 6.1 ± 0.8 | 15.0 ± 5.0 | 4.9 ± 0.3 | |
| CCRF | 84.2 ± 1.5 | 41.3 ± 0.0 | 28.4 ± 4.3 | 8.3 ± 0.3 | 64.3 ± 3.0 | 41.5 ± 1.1 | |
| 2H6 | 88.8 ± 0.6 | 43.3 ± 0.0 | 30.6 ± 4.7 | 8.0 ± 1.7 | 66.0 ± 0.9 | 38.5 ± 0.2 | Dexamethasone |
| A7+ | 26.5 ± 1.0 | 13.5 ± 0.7 | 25.9 ± 3.5 | 5.0 ± 0.8 | 29.6 ± 6.0 | 5.4 ± 0.3 | |
| IC10 | 26.3 ± 2.8 | 13.0 ± 1.5 | 31.9 ± 2.9 | 9.2 ± 1.0 | 37.2 ± 5.5 | 4.3 ± 0.2 | |
| CCRF | 53.6 ± 3.0 | 63.9 ± 4.4 | 17.2 ± 0.1 | 11.5 ± 1.7 | 56.6 ± 6.8 | 51.0 ± 2.2 | |
| 2H6 | 51.5 ± 2.1 | 31.9 ± 2.9 | 14.2 ± 0.4 | 10.0 ± 1.2 | 50.5 ± 0.4 | 35.0 ± 6.2 | VP16 |
| A7+ | 17.2 ± 2.5 | 11.7 ± 4.8 | 16.6 ± 2.3 | 2.9 ± 1.8 | 20.4 ± 1.1 | 9.9 ± 1.9 | |
| IC10 | 20.3 ± 1.2 | 9.4 ± 1.8 | 17.8 ± 1.2 | 10.8 ± 1.0 | 18.9 ± 1.3 | 9.9 ± 1.9 | |
| . | 125I . | 51Cr . | ZVAD-fmk . | ZFA-fmk . | |||
|---|---|---|---|---|---|---|---|
| 125I . | 51Cr . | 125I . | 51Cr . | . | |||
| CCRF | 55.1 ± 0.1 | 28.7 ± 2.0 | 12.1 ± 1.7 | 5.1 ± 0.0 | 48.5 ± 0.1 | 31.2 ± 4.0 | |
| 2H6 | 53.1 ± 1.1 | 37.8 ± 4.0 | 8.2 ± 1.6 | 7.8 ± 1.9 | 57.7 ± 5.4 | 46.4 ± 0.7 | Vinblastine |
| A7+ | 12.6 ± 1.5 | 7.2 ± 1.7 | 9.2 ± 0.4 | 2.7 ± 0.7 | 15.2 ± 2.5 | 7.6 ± 0.5 | |
| IC10 | 12.5 ± 5.9 | 6.8 ± 0.5 | 10.8 ± 2.3 | 6.1 ± 0.8 | 15.0 ± 5.0 | 4.9 ± 0.3 | |
| CCRF | 84.2 ± 1.5 | 41.3 ± 0.0 | 28.4 ± 4.3 | 8.3 ± 0.3 | 64.3 ± 3.0 | 41.5 ± 1.1 | |
| 2H6 | 88.8 ± 0.6 | 43.3 ± 0.0 | 30.6 ± 4.7 | 8.0 ± 1.7 | 66.0 ± 0.9 | 38.5 ± 0.2 | Dexamethasone |
| A7+ | 26.5 ± 1.0 | 13.5 ± 0.7 | 25.9 ± 3.5 | 5.0 ± 0.8 | 29.6 ± 6.0 | 5.4 ± 0.3 | |
| IC10 | 26.3 ± 2.8 | 13.0 ± 1.5 | 31.9 ± 2.9 | 9.2 ± 1.0 | 37.2 ± 5.5 | 4.3 ± 0.2 | |
| CCRF | 53.6 ± 3.0 | 63.9 ± 4.4 | 17.2 ± 0.1 | 11.5 ± 1.7 | 56.6 ± 6.8 | 51.0 ± 2.2 | |
| 2H6 | 51.5 ± 2.1 | 31.9 ± 2.9 | 14.2 ± 0.4 | 10.0 ± 1.2 | 50.5 ± 0.4 | 35.0 ± 6.2 | VP16 |
| A7+ | 17.2 ± 2.5 | 11.7 ± 4.8 | 16.6 ± 2.3 | 2.9 ± 1.8 | 20.4 ± 1.1 | 9.9 ± 1.9 | |
| IC10 | 20.3 ± 1.2 | 9.4 ± 1.8 | 17.8 ± 1.2 | 10.8 ± 1.0 | 18.9 ± 1.3 | 9.9 ± 1.9 | |
DNA fragmentation (% specific 125I-DNA release) and membrane lysis (% specific 51Cr release) of P-gp−ve CCRF, 2H6 and P-gp+ve A7+, IC10, cells treated for 48 hours in 96-well plates (2 × 104cells/well) with VIN (0.1 μg/mL), DEX (20 μg/mL), and VP-16 (0.1 μg/mL). In some wells, cells were preincubated for 30 minutes with 20 μmol/L ZVAD-fmk or control ZFA-fmk inhibitor. Data are calculated as the mean ± SE of triplicate samples and are representative of at least two different experiments. Similar results were observed with at least two other concentrations of each drug (data not shown).